Acutaas Chemicals Limited reported a robust performance for the second quarter of FY27, with revenue from operations increasing by 42.7% year-on-year to ₹4,369 million. The company’s EBITDA saw a significant surge of 84.6% to ₹1,760 million, and Profit After Tax (PAT) grew by 71.4% to ₹1,231 million. The results were driven by strong momentum in the Pharmaceutical Intermediates business.
Acutaas Chemicals Reports Strong Q2 FY27 Financials
Acutaas Chemicals Limited has announced its financial results for the second quarter (Q2) and half year (H1) ended September 30, 2026. The company demonstrated significant year-on-year growth across key financial metrics.
Key Financial Highlights (Q2 FY27)
- Revenue from Operations: Increased by 42.7% to ₹4,369 million (Q2 FY26: ₹3,062 million).
- EBITDA: Surged by 84.6% to ₹1,760 million (Q2 FY26: ₹953 million).
- EBITDA Margin: Improved to 40.3% from 31.1% in the prior year quarter.
- Profit After Tax (PAT): Grew by 71.4% to ₹1,231 million (Q2 FY26: ₹719 million).
- PAT Margin: Increased to 28.2% from 23.5% in Q2 FY26.
Management Commentary
Mr. Naresh Patel, Executive Chairman and Managing Director, stated, “We delivered strong revenue of ₹4,369 million, representing 42.7% year-on-year growth. The performance was led by the continued momentum in our Pharmaceutical Intermediates business, which was offset by softer performance in the Specialty Chemicals segment.” He also highlighted the inauguration of their South Korea manufacturing facility, which is equipped to produce high-purity chemicals for the semiconductor industry. The company has revised its FY27 revenue growth guidance upward to around 25% to 30% and raised its EBITDA margin guidance to 38-40%.
H1 FY27 Performance
For the first half of FY27, Acutaas Chemicals reported total revenue from operations of ₹7,666 million, a growth of 49.3% compared to H1 FY26 (₹5,134 million). EBITDA for H1 FY27 stood at ₹2,890 million, up 97.7% year-on-year, with a corresponding EBITDA margin of 37.7%. PAT for H1 FY27 was ₹1,981 million, an increase of 71.0% over H1 FY26.
Business Segment Performance
The Pharma Intermediates segment showed robust growth, driven by CDMO and Core Advanced intermediate businesses. The Specialty Chemicals segment experienced a decline in Commodity chemicals revenue as part of a strategic phase-out, and the BFC business was impacted by a change in customer ownership.
Source: BSE
